Encapsulation of curcumin within poly(amidoamine) dendrimers for delivery to cancer cells

Journal of Materials Science: Materials in Medicine

Volumn 24, Issue 9, 2013, Pages 2137-2144

  Wang, Lu ^a,b   Xu, Xiaoping ^a,b   Zhang, Yi ^a,b   Zhang, Yuanqing ^a,b   Zhu, Ying ^a   Shi, Jiye ^a,c   Sun, Yanhong ^a   Huang, Qing ^a  

^a SHANGHAI INSTITUTE OF APPLIED PHYSICS   (China)

^b UNIVERSITY OF CHINESE ACADEMY OF SCIENCES   (China)

^c UCB PHARMA   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI-PROLIFERATIVE ACTIVITIES; ANTICANCER ACTIVITIES; DRUG DELIVERY SYSTEM; MITOCHONDRIAL MEMBRANE POTENTIAL; POLYAMIDOAMINE DENDRIMERS; PROTEIN EXPRESSIONS; REACTIVE OXYGEN SPECIES; WATER SOLUBILITIES;

BIOCHEMISTRY; CELL CULTURE; CELL DEATH; DENDRIMERS; DRUG DELIVERY;

SOLUBILITY;

CURCUMIN; DENDRIMER; POLYAMIDOAMINE; PROTEIN BAX; REACTIVE OXYGEN METABOLITE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; DRUG RELEASE; DRUG SOLUBILITY; ENCAPSULATION; HUMAN; HUMAN CELL; MITOCHONDRIAL MEMBRANE POTENTIAL; PRIORITY JOURNAL; SUSTAINED RELEASE FORMULATION;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CHEMISTRY, PHARMACEUTICAL; CURCUMIN; DENDRIMERS; DRUG CARRIERS; HUMANS; NEOPLASMS;

EID: 84884282751     PISSN: 09574530     EISSN: 15734838     Source Type: Journal    
DOI: 10.1007/s10856-013-4969-3     Document Type: Article

References (27)

1. Aggarwal BB, Kumar A, Bharti AC. Anticancer potential of curcumin: preclinical and clinical studies. Anticancer Res. 2003;23(1A):363-98.
2. Bar-Sela G, Epelbaum R, Schaffer M. Curcumin as an anti-cancer agent: review of the gap between basic and clinical applications. Curr Med Chem. 2010;17(3):190-7.
3. Reuter S, Eiffes S, Dicato M, Aggarwal BB, Diederich M. Modulation of antiapoptotic and survival pathways by curcumin as a strategy to induce apoptosis in cancer cells. Biochem Pharmacol. 2008;76(11):1340-51.
4. Cheng AL, Hsu CH, Lin JK, Hsu MM, Sheen TS, Ho YF, Ko JY, Lin JT, Wu MS, Jee SH. Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or premalignant lesions. Anticancer Res. 2001;21(4B):2895-900.
5. Sharma RA, Euden SA, Platton SL, Cooke DN, Shafayat A, Hewitt HR. Phase I clinical trial of oral curcumin: biomarkers of systemic activity and compliance. Clin Cancer Res. 2004;10:6847-54.
6. Anand P, Kunnumarkkara AB, Newman RA, Aggarwal BB. Bioavailability of curcumin: problems and promise. Mol Pharm. 2007;4(6):807-18.
7. Dhilon N, Aggarwal BB, Newman RA, Wolff RA, Kunnumakkara AB, Abbruzzese JL. Phase II trail of curcumin in patients with advanced pancreatic cancer. Clin Cancer Res. 2008;14(14):4491-9.
8. Markatou E, Gionis V, Chryssikos GD, Hatziantoniou S, Georgopoulos A, Demetzos C. Molecular interactions between dimethoxycurcumin and pamam dendrimer carriers. Int J Pharm. 2007;339:231-6.
9. Lin HP, Kuo LK, Chuu CP. Combined treatment of curcumin and small molecule inhibitors suppresses proliferation of A549 and H1299 human non-small-cell lung cancer cells. Phytother Res. 2012;26(1):122-6.
10. Majoros IJ, Myc A, Thomas TP, Mehta CB, Baker JR Jr. Dendrimer-based multifunctional conjugate for cancer therapy: synthesis, characterization, and functionality. Biomacromolecules. 2006;7(2):572-9.
11. Thomas TP, Majoros IJ, Kotlyar A, Kukowska-Latallo JF, Bielinska A, Myc A, Baker JR Jr. Targeting and inhibition of cell growth by an engineered dendritic nanodevice. J Med Chem. 2005;48(11):3729-35.
12. Majoros IJ, Thomas TP, Mehta CB, Baker JR Jr. Poly(amidoamine) dendrimer-based multifunctional engineered nanodevice for cancer therapy. J Med Chem. 2005;48(19):5892-9.
13. Tang H, Murphy CJ, Zhang B, Shan Y, Van Kirk EA, Murdoch WJ, Radosz M. Curcumin polymers as anticancer conjugates. Biomaterials. 2010;31(27):7139-49.
14. Youssef D, Nichols CE, Cameron TS, Balzarini J, Clercq ED, Jha A. Design, synthesis, and cytostatic activity of novel cyclic curcumin analogues. Bioorg Med Chem Lett. 2007;17(20):5624-9.
15. Shi W, Dola S, Rizk S, Hussain A, Tariq H, Averick S, Amoreaux WL, Idrissi AEl ‡, Banerjee P, Raja K. Synthesis of monofunctional curcumin derivatives, clicked curcumin dimer, and a pamam dendrimer curcumin conjugate for therapeutic applications. Org Lett. 2007;l(26):5461-4.
16. Yang W, Cheng YY, Xu T, Wang X, Wen LP. Targeting cancer cells with biotin-dendrimer conjugates. Eur J Med Chem. 2009;44(2):862-8.
17. Kurien BT, Singh A, Matsumoto H, Scofield RH. Improving the solubility and pharmacological efficacy of curcumin by heat treatment. Assay Drug Dev Technol. 2007;5(4):567-86.
18. Chen QY, Wang YY, Xu KD, Lu GH. Curcumin induces apoptosis in human lung adenocarcinoma A549 cells through a reactive oxygen species-dependent mitochondrial signaling pathway. Oncol Rep. 2010;23(2):397-403.
19. Li L, Aggarwal BB, Shishodia S, Abbruzzese J, Kurzrock R. Nuclear factor-kappa B and I kappa B kinase are constitutively active in human pancreatic cells, and their down-regulation by curcumin (diferuloylmethane) is associated with the suppression of proliferation and the induction of apoptosis. Cancer. 2004;101(10):2351-62.
20. Li L, Braiteh FS, Kurzrock R. Liposome-encapsulated curcumin: in vitro and in vivo effects on proliferation, apoptosis, signaling, and angiogenesis. Cancer. 2005;104(6):1322-31.
21. Chen QY, Lu GH, Wu YQ. Curcumin induces mitochondria pathway mediated cell apoptosis in A549 lung adenocarcinoma cells. Oncol Rep. 2010;23(5):1285-92.
22. Barzegar A, Moosavi-Movahedi AA. Intracellular ROS protection efficiency and free radical-scavenging activity of curcumin. PLoS ONE. 2011;6(10):e26012.
23. Hidaka H, Ishiko T, Furuhashi T, Kamohara H, Suzuki S, Miyazaki M, Ikeda O, Mita S, Setoguchi T, Ogawa M. Curcumin inhibits interleukin 8 production and enhances interleukin 8 receptor expression on the cell surface-impact on human pancreatic carcinoma cell growth by autocrine regulation. Cancer. 2002;95:1206-14.
24. Ko JC, Tsa MS, Weng SH, Kuo YH, Chiu YF, Lin YW. Curcumin enhances the mitomycin C-induced cytotoxicity via downregulation of MKK1/2-ERK1/2-mediated Rad51 expression in non-small cell lung cancer cells. Toxicol Appl Pharm. 2011;255(3):327-38.
25. Farrow SN, White JHM, Martinou I, Raven T, Pun KT, Grinham CJ, Martinou JC, Brown R. Cloning of a Bcl-2 homologue by interaction with adenovirus EIB 19K. Nature. 1995;374:731-3.
26. Yang E, Zha L, Jockel J, Boise LH, Thompson CB, Korsmeyer SJ. Bad, a heterodimeric partner for Bcl-XL and Bcl-2 displaces Bax and promotes death. Cell. 1995;80(2):285-91.
27. Boise LH, Gonzalez OM, Postema CE, Ding L, Lindsten T, Turka LA, Mao X, Nunez O, Thompson CB. Bcl-x, a Bcl-2-related gene that functions as a dominant regulator of apoptotic cell death. Cell. 1993;74(4):597-608.